Interferon (IFN)-γ-mediated inflammation and the kynurenine pathway in relation to bone mineral density: The Hordaland Health Study

Clinical and Experimental Immunology

Volumn 176, Issue 3, 2014, Pages 452-460

  Apalset, E M ^a,b   Gjesdal, C G ^a,b   Ueland, P M ^a,b   Midttun, O ^c   Ulvik, A ^c   Eide, G E ^a,b   Meyer, K ^c   Tell, G S ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c BEVITAL AS   (Norway)

Author keywords

Bone mineral density; Inflammation; Kynurenine pathway; Neopterin; Osteoporosis

Indexed keywords

3 HYDROXYANTHRANILIC ACID; BIOLOGICAL MARKER; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; KYNURENINE; NEOPTERIN; TRYPTOPHAN; XANTHURENIC ACID;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE DENSITY; BONE METABOLISM; DEGRADATION; FEMALE; HIP; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLAMMATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT;

BONE MINERAL DENSITY; INFLAMMATION; KYNURENINE PATHWAY; NEOPTERIN; OSTEOPOROSIS;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; KYNURENINE; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; MIDDLE AGED; NEOPTERIN; RISK FACTORS; TRYPTOPHAN;

EID: 84899056031     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12288     Document Type: Article

References (62)

1. Hardy R, Cooper MS. Bone loss in inflammatory disorders. J Endocrinol 2009; 201:309-320.
2. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337-342.
3. Nakashima T, Hayashi M, Fukunaga T etal. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011; 17:1231-1234.
4. Kong YY, Feige U, Sarosi I etal. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402:304-309.
5. Gao Y, Grassi F, Ryan MR etal. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007; 117:122-132.
6. Schultz DR, Arnold PI. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum 1990; 20:129-147.
7. de Pablo P, Cooper MS, Buckley CD. Association between bone mineral density and C-reactive protein in a large population-based sample. Arthritis Rheum 2012; 64:2624-2631.
8. Koh JM, Khang YH, Jung CH etal. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporos Int 2005; 16:1263-1271.
9. Bhupatihiraju SN, Alekel DL, Stewart JW etal. Relationship of circulating total homocysteine and C-reactive protein to trabecular bone in postmenopausal women. J Clin Densitom 2007; 10:395-403.
10. Schett G, Kiechl S, Weger S etal. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 2006; 166:2495-2501.
11. Ganesan K, Teklehaimanot S, Tran TH, Asuncion M, Norris K. Relationship of C-reactive protein and bone mineral density in community-dwelling elderly females. J Natl Med Assoc 2005; 97:329-333.
12. Taubman MA, Kawai T. Involvement of T-lymphocytes in periodontal disease and in direct and indirect induction of bone resorption. Crit Rev Oral Biol Med 2001; 12:125-135.
13. van Roon JA, Glaudemans KA, Bijlsma JW, Lafeber FP. Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62:113-119.
14. Weitzmann MN, Pacifici R. T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Ann NY Acad Sci 2007; 1116:360-375.
15. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev 2008; 29:403-440.
16. Huber C, Batchelor JR, Fuchs D etal. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160:310-316.
17. Munn DH, Sharma MD, Lee JR etal. Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase. Science 2002; 297:1867-1870.
18. Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006; 364:82-90.
19. Fuchs D, Moller AA, Reibnegger G, Stockle E, Werner ER, Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990; 3:873-876.
20. Ozaki Y, Edelstein MP, Duch DS. Induction of indoleamine 2, 3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc Natl Acad Sci USA 1988; 85:1242-1246.
21. Thomas SM, Garrity LF, Brandt CR etal. IFN-gamma-mediated antimicrobial response. Indoleamine 2, 3-dioxygenase-deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplasma growth. J Immunol 1993; 150:5529-5534.
22. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003; 24:242-248.
23. Trabanelli S, Ocadlikova D, Evangelisti C, Parisi S, Curti A. Induction of regulatory T cells by dendritic cells through indoleamine 2, 3-dioxygenase: a potent mechanism of acquired peripheral tolerance. Curr Med Chem 2011; 18:2234-2239.
24. Le Floc'h N, Otten W, Merlot E. Tryptophan metabolism, from nutrition to potential therapeutic applications. Amino Acids 2010; 41:1195-1205.
25. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189:1363-1372.
26. Kikuiri T, Kim I, Yamaza T etal. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res 2010; 25:1668-1679.
27. Nakashima T, Takayanagi H. Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol 2009; 29:555-567.
28. Yuan FL, Li X, Lu WG etal. Regulatory T cells as a potent target for controlling bone loss. Biochem Biophys Res Commun 2010; 402:173-176.
29. Arshadi D, Nikbin B, Shakiba Y, Kiani A, Jamshidi AR, Boroushaki MT. Plasma level of neopterin as a marker of disease activity in treated rheumatoid arthritis patients: association with gender, disease activity and anti-CCP antibody. Int Immunopharmacol 2013; 17:763-767.
30. Schroecksnadel K, Kaser S, Ledochowski M etal. Increased degradation of tryptophan in blood of patients with rheumatoid arthritis. J Rheumatol 2003; 30:1935-1939.
31. Pertovaara M, Hasan T, Raitala A etal. Indoleamine 2, 3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin Exp Immunol 2007; 150:274-278.
32. Pertovaara M, Raitala A, Uusitalo H etal. Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjögren's syndrome. Clin Exp Immunol 2005; 142:155-161.
33. Pedersen ER, Midttun O, Ueland PM etal. Systemic markers of interferon-gamma-mediated immune activation and long-term prognosis in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2011; 31:698-704.
34. Widner B, Laich A, Sperner-Unterweger B, Ledochowski M, Fuchs D. Neopterin production, tryptophan degradation, and mental depression - what is the link? Brain Behav Immun 2002; 16:590-595.
35. Widner B, Leblhuber F, Fuchs D. Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J Neural Transm 2002; 109:181-189.
36. Forrest CM, Mackay GM, Oxford L, Stoy N, Stone TW, Darlington LG. Kynurenine pathway metabolism in patients with osteoporosis after 2 years of drug treatment. Clin Exp Pharmacol Physiol 2006; 33:1078-1087.
37. Gjesdal CG, Vollset SE, Ueland PM, Refsum H, Meyer HE, Tell GS. Plasma homocysteine, folate, and vitamin B 12 and the risk of hip fracture: the Hordaland Homocysteine Study. J Bone Miner Res 2007; 22:747-756.
38. Konstantinova SV, Tell GS, Vollset SE, Ulvik A, Drevon CA, Ueland PM. Dietary patterns, food groups, and nutrients as predictors of plasma choline and betaine in middle-aged and elderly men and women. Am J Clin Nutr 2008; 88:1663-1669.
39. Midttun O, Hustad S, Ueland PM. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2009; 23:1371-1379.
40. Hustad S, Eussen S, Midttun O etal. Kinetic modeling of storage effects on biomarkers related to B vitamin status and one-carbon metabolism. Clin Chem 2012; 58:402-410.
41. Gjesdal CG, Aanderud SJ, Haga HJ, Brun JG, Tell GS. Femoral and whole-body bone mineral density in middle-aged and older Norwegian men and women: suitability of the reference values. Osteoporos Int 2004; 15:525-534.
42. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
43. Russell RG, Espina B, Hulley P. Bone biology and the pathogenesis of osteoporosis. Curr Opin Rheumatol 2006; 18 (Suppl 1):S3-10.
44. Oxenkrug GF. Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism. Ann NY Acad Sci 2010; 1199:1-14.
45. Pertovaara M, Raitala A, Juonala M etal. Indoleamine 2, 3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol 2007; 148:106-111.
46. Theofylaktopoulou D, Midttun O, Ulvik A etal. A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. Clin Exp Immunol 2013; 173:121-130.
47. Pertovaara M, Heliovaara M, Raitala A, Oja SS, Knekt P, Hurme M. The activity of the immunoregulatory enzyme indoleamine 2, 3-dioxygenase is decreased in smokers. Clin Exp Immunol 2006; 145:469-473.
48. Tankiewicz A, Pawlak D, Topczewska-Bruns J, Buczko W. Kidney and liver kynurenine pathway enzymes in chronic renal failure. Adv Exp Med Biol 2003; 527:409-414.
49. Kanis JA, McCloskey EV. Risk factors in osteoporosis. Maturitas 1998; 30:229-233.
50. Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem 2004; 37:684-687.
51. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007; 7:292-304.
52. Takayanagi H, Sato K, Takaoka A, Taniguchi T. Interplay between interferon and other cytokine systems in bone metabolism. Immunol Rev 2005; 208:181-193.
53. Duque G, Huang DC, Dion N etal. Interferon-gamma plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice. J Bone Miner Res 2011; 26:1472-1483.
54. Zupan J, Komadina R, Marc J. The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatroy cyokines differs in human osteoporotic and osteoarthritic bone tissues. J Biomed Sci 2012; 19:28.
55. Sucher R, Schroecksnadel K, Weiss G etal. Neopterin, a prognostic marker in human malignancies. Cancer Lett 2010; 287:13-22.
56. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 1992; 29:307-341.
57. Hoffmann G, Wirleitner B, Fuchs D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res 2003; 52:313-321.
58. Abu-Amer Y. Inflammation, cancer and bone loss. Curr Opin Pharmacol 2009; 9:427-433.
59. Krause D, Suh HS, Tarassishin L etal. The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1. Am J Pathol 2011; 179:1360-1372.
60. Malina HZ. System in biology leading to cell pathology: stable protein-protein interactions after covalent modifications by small molecules or in transgenic cells. J Biomed Sci 2011; 18:7.
61. Malina HZ, Richter C, Mehl M, Hess OM. Pathological apoptosis by xanthurenic acid, a tryptophan metabolite: activation of cell caspases but not cytoskeleton breakdown. BMC Physiol 2001; 1:7.
62. Khosla S, Melton LJ 3rd, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res 2011; 26:441-451.